Insilico Medicine and Luoxin sign a long-term AI drug discovery pact for chronic diseases
Insilico will provide target discovery, data analysis and molecule design for digestive, metabolic and other non-cancer chronic diseases, with Luoxin handling disease expertise and validation; no financial terms were given.